Use of secondary preventive drugs in patients with acute coronary syndromes treated medically or with coronary angioplasty: results from the nationwide French PREVENIR survey
about
sameAs
Exploring the equity of GP practice prescribing rates for selected coronary heart disease drugs: a multiple regression analysis with proxies of healthcare needThe use of lipid-lowering therapy for secondary prevention in patients undergoing percutaneous coronary interventionHow equitable are GP practice prescribing rates for statins?: an ecological study in four primary care trusts in North West EnglandAre GP practice prescribing rates for coronary heart disease drugs equitable? A cross sectional analysis in four primary care trusts in England.Management and in-hospital outcome of patients with acute myocardial infarction admitted to intensive care units at the turn of the century: results from the French nationwide USIC 2000 registry.Achieving lipid goals in Europe: how large is the treatment gap?Present and future of secondary prevention after an acute coronary syndrome.Undertreatment of coronary heart disease in patients undergoing coronary artery bypass surgery.Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nationwide French registry.Cardiac rehabilitation reduces the rate of major adverse cardiac events after percutaneous coronary intervention.Prescription at discharge of recommended treatments for secondary prevention in patients with ST-segment elevation myocardial infarction according to reperfusion strategies. Results from the IN-ACS outcome study
P2860
Q24804642-49440433-73CE-49A2-B8ED-A8273B17AAFFQ28196775-D81E075C-B4F6-40AB-A067-D3769AFE98A6Q28221444-CC293DEC-F237-4E92-8104-E46F4033E8B2Q35414428-8E570B10-3ADF-47EE-9456-1E1F6847B127Q35583175-CB43EEC9-58B4-4CBB-9710-11C89D038C72Q35777411-20C65B94-CF58-438E-BD34-D3FC95F9E7A1Q36118008-9010165A-26F3-456C-A12B-9C3BAA652FA8Q42831712-B245A429-2374-4998-838B-018D80A5C102Q45073971-9E4465FB-67D4-4DE2-8A5A-E030A4B063E3Q51460171-890A6566-C32F-44E9-9774-E6F47BC8553EQ56991534-26154FD7-E4BC-4D7F-B347-71E76B16F6DB
P2860
Use of secondary preventive drugs in patients with acute coronary syndromes treated medically or with coronary angioplasty: results from the nationwide French PREVENIR survey
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Use of secondary preventive dr ...... ionwide French PREVENIR survey
@ast
Use of secondary preventive dr ...... ionwide French PREVENIR survey
@en
Use of secondary preventive dr ...... ionwide French PREVENIR survey
@nl
type
label
Use of secondary preventive dr ...... ionwide French PREVENIR survey
@ast
Use of secondary preventive dr ...... ionwide French PREVENIR survey
@en
Use of secondary preventive dr ...... ionwide French PREVENIR survey
@nl
prefLabel
Use of secondary preventive dr ...... ionwide French PREVENIR survey
@ast
Use of secondary preventive dr ...... ionwide French PREVENIR survey
@en
Use of secondary preventive dr ...... ionwide French PREVENIR survey
@nl
P2093
P2860
P356
P1433
P1476
Use of secondary preventive dr ...... ionwide French PREVENIR survey
@en
P2093
P2860
P304
P356
10.1136/HEART.88.2.159
P407
P577
2002-08-01T00:00:00Z